Coherus Oncology 2025 Q2 Earnings Strong Turnaround with 2404.5% Net Income Surge

Coherus Oncology reported its 2025 Q2 earnings on August 8, marking a significant financial turnaround. The results surpassed expectations, with the company posting a net income of $297.77 million, a 2404.5% increase from a net loss of $12.92 million in the same period last year. Management guided for continued momentum, citing robust pipeline readouts and extended cash runway.

Revenue
Coherus Oncology reported total net revenue of $10.25 million in Q2 2025, a 0.4% decline from $10.30 million in Q2 2024. LOQTORZI, the company's flagship product, contributed $9.96 million to the revenue, representing a 36% year-over-year increase. Additional revenue streams brought in $295,000, rounding out the total net revenue for the quarter.

Earnings/Net Income
Coherus returned to profitability with an EPS of $2.57 for Q2 2025, a sharp reversal from a loss of $0.11 per share in Q2 2024—a 2436.4% positive change. The company reported net income of $297.77 million, a 2404.5% increase from the previous year’s net loss of $12.92 million. The significant improvement in profitability reflects effective cost management and strong commercial execution.

Price Action
The stock price of Coherus Oncology fell 3.92% during the latest trading day and declined 5.99% over the full trading week. However, it managed an 8.83% gain month-to-date, showing some short-term positive momentum despite the drop post-earnings.

Post-Earnings Price Action Review
The 30-day post-earnings strategy for Coherus Oncology shares performed poorly, resulting in an 85.42% loss over the past three years. This significantly underperformed the benchmark return of 47.91%, with an excess return of -133.34% and a CAGR of -47.78%. The strategy showed a maximum drawdown of 0.00% and a negative Sharpe ratio of -0.48, indicating high volatility and risk. Despite the earnings beat, investor sentiment did not translate into strong stock performance.

CEO Commentary
Denny Lanfear, Coherus Chairman and CEO, emphasized the company’s strong commercial execution, highlighting a 36% increase in LOQTORZI net revenue to $10.0 million in Q2 2025. He expressed confidence in the company’s cash runway extending through 2026, driven by key data readouts expected in early 2026. Lanfear also underscored the potential for anti-CCR8 therapies to become foundational in solid tumor treatment and the growing international licensing opportunities.

Guidance
Coherus anticipates data readouts for CHS-114 and casdozokitug in early 2026, including initial results from Phase 1b studies in head and neck, gastric, and esophageal cancers, as well as the Phase 2 trial in hepatocellular carcinoma. These readouts are expected to provide clarity on the clinical potential of its pipeline candidates and support the company's long-term strategic goals.

Additional News
Recent global headlines include increased tensions over the Gaza plan and international diplomatic efforts to avert a full Israeli occupation. In economic news, Trump announced a policy to exclude illegal immigrants from the U.S. census, and the U.S. Federal Reserve welcomed a key economic adviser from his administration. In Asia, India responded to higher tariffs, while a Chinese film on the Nanjing Massacre made its U.S. debut. In Europe, Portugal extended its national alert amid severe wildfires, and the EU’s pharmaceutical sector braced for potential U.S. tariff impacts. In Africa, multiple nations reported tragic incidents, including a fatal helicopter crash in Ghana and a plane crash in Algeria.